- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 90,120 | 24.06.24 13:06:52 | +1,800 | +2,04% | 90,540 | 90,710 | 88,290 | 88,320 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 984,600 | 24.06.24 08:12:32 | -3,000 | -0,30% | 991,800 | 997,200 | 984,600 | 987,600 |
